← Back to Patent Explorer
US5273875A Expired / Lapsed US ⏱️ 0.0 years remaining

N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body

Assignee: Cornell Research Foundation Inc
•
Filing: 1992-04-08
•
Granted: 1993-12-28
•
Expires: 2012-04-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Physiologically active N 6 -(hydrazinoiminomethyl)lysine or pharmaceutically acceptable acid addition salt thereof is administered in a nitric oxide synthesis inhibiting amount to a subject in need of such inhibition (e.g., a subject with low blood pressure, e.g., due to sepsis or to therapeutic administration of cytokines, or needing immunosuppressive effect) or is added to a medium containing isolated organs, intact cells, cell homogenates or tissue homogenates in an amount sufficient to inhibit nitric oxide formation to elucide or control the biosynthesis, metabolism or physiological role of nitric oxide. Comp This invention was made at least in part with Government support under National Institutes of Health grant number DK 37116. The Government has certain rights in the invention.

Inventors

  • 👤 Owen W. Griffith

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 08:58
CPC Classifications
C; C07; C07C; C07C281/00; C07C281/16

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 53 words
A method for controlling the biosynthesis, metabolism or physiological role of nitric oxide in vitro, comprising adding physiologically active N 6 -(hydrazinoiminomethyl)lysine an acid addition salt thereof, in an amount sufficient to inhibit nitric oxide formation from arginine to a medium containing isolated organs, intact cells, cell homogenates or tissue homogenates from mammals.
Claim 2
Independent Claim 53 words
A method for controlling the biosynthesis, metabolism or physiological role of nitric oxide in vitro, comprising adding physiologically active N 6 -(hydrazinoiminomethyl)lysine an acid addition salt thereof, in an amount sufficient to inhibit nitric oxide formation from arginine to a medium containing isolated organs, intact cells, cell homogenates or tissue homogenates from mammals.

References Cited (Backward Citations)

US4282217A Cited
US4698442A Cited
US5028627A Cited
US5059712A Cited
EP0446699A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-12-27 1997-06-28 1997-12-28 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-12-27 2001-06-28 2001-12-28 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-12-27 2005-06-28 2005-12-28 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag